Pharmacogenomics of adverse drug reactions: Implementing personalized medicine

Human Molecular Genetics

Volumn 21, Issue R1, 2012, Pages

  Wei, Chun Yu ^a   Michael lee, Ming Ta ^a,b,c   Chen, Yuan Tsong ^a,d  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c RIKEN   (Japan)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DRUG METABOLIZING ENZYME;

ADVERSE DRUG REACTION; ALLELE; ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG TRANSPORT; GENETIC ASSOCIATION; GENETIC VARIABILITY; HLA SYSTEM; HUMAN; INBORN ERROR OF METABOLISM; LIVER INJURY; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; RISK ASSESSMENT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

BIOLOGICAL TRANSPORT; DRUG HYPERSENSITIVITY; DRUG TOXICITY; GENETIC MARKERS; GENETIC VARIATION; HLA ANTIGENS; HUMANS; INDIVIDUALIZED MEDICINE; METABOLIC DETOXICATION, DRUG; PHARMACOGENETICS;

EID: 84867129742     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds341     Document Type: Article

References (73)

1. Evans, W.E. and Relling, M.V. (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487-491.
2. Meyer, U.A. (2004) Pharmacogenetics-five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet., 5, 669-676.
3. Savonarola, A., Palmirotta, R., Guadagni, F. and Silvestris, F. (2012) Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. Pharmacogenomics J, 12, 277-286.
4. Ong, F.S., Deignan, J.L., Kuo, J.Z., Bernstein, K.E., Rotter, J.I., Grody, W.W. and Das, K. (2012) Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics, 13, 465-475.
5. Lazarou, J., Pomeranz, B.H. and Corey, P.N. (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 279, 1200-1205.
6. Severino, G. and Del Zompo, M. (2004) Adverse drug reactions: role of pharmacogenomics. Pharmacol. Res., 49, 363-373.
7. Need, A.C., Motulsky, A.G. and Goldstein, D.B. (2005) Priorities and standards in pharmacogenetic research. Nat. Genet., 37, 671-681.
8. Pirmohamed, M., Naisbitt, D.J., Gordon, F. and Park, B.K. (2002) The danger hypothesis-potential role in idiosyncratic drug reactions. Toxicology, 181-182, 55-63.
9. Pirmohamed, M. and Park, B.K. (2001) Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci., 22, 298-305.
10. Amur, S., Frueh, F.W., Lesko, L.J. and Huang, S.M. (2008) Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark. Med., 2, 305-311.
11. Ingelman-Sundberg, M., Oscarson, M. and McLellan, R.A. (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci., 20, 342-349.
12. Kirchheiner, J., Henckel, H.B., Franke, L., Meineke, I., Tzvetkov, M., Uebelhack, R., Roots, I. and Brockmoller, J. (2005) Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet. Genomics, 15, 579-587.
13. Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.L., Licinio, J., Roots, I. and Brockmoller, J. (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry, 9, 442-473.
14. Crews, K.R., Gaedigk, A., Dunnenberger, H.M., Klein, T.E., Shen, D.D., Callaghan, J.T., Kharasch, E.D. and Skaar, T.C. (2012) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther., 91, 321-326.
15. Mega, J.L., Simon, T., Collet, J.P., Anderson, J.L., Antman, E.M., Bliden, K., Cannon, C.P., Danchin, N., Giusti, B., Gurbel, P. et al. (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA, 304, 1821-1830.
16. Eichelbaum, M., Ingelman-Sundberg, M. and Evans, W.E. (2006) Pharmacogenomics and individualized drug therapy. Annu. Rev. Med., 57, 119-137.
17. Schaeffeler, E., Fischer, C., Brockmeier, D., Wernet, D., Moerike, K., Eichelbaum, M., Zanger, U.M. and Schwab, M. (2004) Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics, 14, 407-417.
18. Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K. and Hasegawa, Y. (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res., 60, 6921-6926.
19. Yuan, H.Y., Chen, J.J., Lee, M.T., Wung, J.C., Chen, Y.F., Charng, M.J., Lu, M.J., Hung, C.R., Wei, C.Y., Chen, C.H. et al. (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet., 14, 1745-1751.
20. Gullov, A.L., Koefoed, B.G. and Petersen, P. (1994) Bleeding complications to long-term oral anticoagulant therapy. J. Thromb. Thrombolysis, 1, 17-25.
21. Cooper, G.M., Johnson, J.A., Langaee, T.Y., Feng, H., Stanaway, I.B., Schwarz, U.I., Ritchie, M.D., Stein, C.M., Roden, D.M., Smith, J.D. et al. (2008) A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood, 112, 1022-1027.
22. Takahashi, H. and Echizen, H. (2001) Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet., 40, 587- 603.
23. Bell, R.G. and Matschiner, J.T. (1972) Warfarin and the inhibition of vitamin K activity by an oxide metabolite. Nature, 237, 32-33.
24. Takeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N., Whittaker, P., Ranganath, V., Kumanduri, V., McLaren, W. et al. (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet., 5, e1000433.
25. Klein, T.E., Altman, R.B., Eriksson, N., Gage, B.F., Kimmel, S.E., Lee, M.T., Limdi, N.A., Page, D., Roden, D.M., Wagner, M.J. et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med., 360, 753-764.
26. Limdi, N.A., Wadelius, M., Cavallari, L., Eriksson, N., Crawford, D.C., Lee, M.T., Chen, C.H., Motsinger-Reif, A., Sagreiya, H., Liu, N. et al. (2010) Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood, 115, 3827-3834.
27. Gonzalez, F.J. and Fernandez-Salguero, P. (1995) Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol. Sci., 16, 325-327.
28. van Kuilenburg, A.B. (2006) Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question. Cancer Invest., 24, 215-217.
29. Giacomini, K.M., Huang, S.M., Tweedie, D.J., Benet, L.Z., Brouwer, K.L., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K.M. et al. (2010) Membrane transporters in drug development. Nat. Rev. Drug Discov., 9, 215-236.
30. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H.P., Brockmoller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA, 97, 3473-3478.
31. Hauser, I.A., Schaeffeler, E., Gauer, S., Scheuermann, E.H., Wegner, B., Gossmann, J., Ackermann, H., Seidl, C., Hocher, B., Zanger, U.M. et al. (2005) ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J. Am. Soc. Nephrol., 16, 1501-1511.
32. Cusatis, G., Gregorc, V., Li, J., Spreafico, A., Ingersoll, R.G., Verweij, J., Ludovini, V., Villa, E., Hidalgo, M., Sparreboom, A. et al. (2006) Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl Cancer Inst., 98, 1739-1742.
33. Ballantyne, C.M. (2004) Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction. Am. Heart J., 148, S3-S8.
34. Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., Gut, I., Lathrop, M. and Collins, R. (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med., 359, 789-799.
35. Konig, J., Seithel, A., Gradhand, U. and Fromm, M.F. (2006) Pharmacogenomics of human OATP transporters. Naunyn. Schmiedebergs Arch. Pharmacol., 372, 432-443.
36. Voora, D., Shah, S.H., Spasojevic, I., Ali, S., Reed, C.R., Salisbury, B.A. and Ginsburg, G.S. (2009) The SLCO1B1*5 variant is associated with statin-induced side effects. J. Am. Coll. Cardiol., 54, 1609-1616.
37. Puccetti, L., Ciani, F. and Auteri, A. (2010) Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis, 211, 28-29.
38. Wilke, R.A., Ramsey, L.B., Johnson, S.G., Maxwell, W.D., McLeod, H.L., Voora, D., Krauss, R.M., Roden, D.M., Feng, Q., Cooper-Dehoff, R.M. et al. (2012) The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy. Clin. Pharmacol. Ther., 92, 112-117.
39. Hung, S.I., Chung, W.H., Jee, S.H., Chen, W.C., Chang, Y.T., Lee, W.R., Hu, S.L., Wu, M.T., Chen, G.S., Wong, T.W. et al. (2006) Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics, 16, 297-306.
40. Kim, S.H., Choi, J.H., Lee, K.W., Shin, E.S., Oh, H.B., Suh, C.H., Nahm, D.H. and Park, H.S. (2005) The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin. Exp. Allergy, 35, 339- 344.
41. Kim, S.H., Ye, Y.M., Lee, S.K. and Park, H.S. (2006) Genetic mechanism of aspirin-induced urticaria/angioedema. Curr. Opin. Allergy Clin. Immunol., 6, 266-270.
42. Ozeki, T., Mushiroda, T., Yowang, A., Takahashi, A., Kubo, M., Shirakata, Y., Ikezawa, Z., Iijima, M., Shiohara, T., Hashimoto, K. et al. (2010) Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet., 20, 1034-1041.
43. McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J.J., Kasperaviciute, D., Carrington, M., Sills, G.J., Marson, T., Jia, X., de Bakker, P.I. et al. (2011) HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med., 364, 1134-1143.
44. Hughes, A.R., Mosteller, M., Bansal, A.T., Davies, K., Haneline, S.A., Lai, E.H., Nangle, K., Scott, T., Spreen, W.R., Warren, L.L. et al. (2004) Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics, 5, 203- 211.
45. Rudolph, M.G., Stanfield, R.L. and Wilson, I.A. (2006) How TCRs bind MHCs, peptides, and coreceptors. Annu. Rev. Immunol., 24, 419-466.
46. Nassif, A., Bensussan, A., Boumsell, L., Deniaud, A., Moslehi, H., Wolkenstein, P., Bagot, M. and Roujeau, J.C. (2004) Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol., 114, 1209-1215.
47. Pichler, W.J. (2003) Delayed drug hypersensitivity reactions. Ann. Intern. Med., 139, 683-693.
48. Padovan, E., Bauer, T., Tongio, M.M., Kalbacher, H. and Weltzien, H.U. (1997) Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy. Eur. J. Immunol., 27, 1303-1307.
49. Pichler, W.J., Beeler, A., Keller, M., Lerch, M., Posadas, S., Schmid, D., Spanou, Z., Zawodniak, A. and Gerber, B. (2006) Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol. Int., 55, 17-25.
50. Wei, C.Y., Chung, W.H., Huang, H.W., Chen, Y.T. and Hung, S.I. (2012) Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J. Allergy Clin. Immunol, 129, 1562-1569.
51. Ou Yang, C.W., Hung, S.I., Juo, C.G., Lin, Y.P., Fang, W.H., Lu, I.H., Chen, S.T. and Chen, Y.T. (2007) HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. J. Allergy Clin. Immunol., 120, 870-877.
52. Chasman, D.I., Posada, D., Subrahmanyan, L., Cook, N.R., Stanton, V.P. Jr and Ridker, P.M. * Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA, 291, 2821-2827.
53. Nieminen, T., Kahonen, M., Viiri, L.E., Gronroos, P. and Lehtimaki, T. (2008) Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics, 9, 1475-1486.
54. Zintzaras, E., Kitsios, G.D., Triposkiadis, F., Lau, J. and Raman, G. (2009) APOE gene polymorphisms and response to statin therapy. Pharmacogenomics J., 9, 248-257.
55. Voora, D., Shah, S.H., Reed, C.R., Zhai, J., Crosslin, D.R., Messer, C., Salisbury, B.A. and Ginsburg, G.S. (2008) Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ. Cardiovasc. Genet., 1, 100-106.
56. Superko, H.R., Momary, K.M. and Li, Y. (2012) Statins personalized. Med. Clin. North Am., 96, 123-139.
57. Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A.M., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D. et al. (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 359, 727-732.
58. Hung, S.I., Chung, W.H., Liou, L.B., Chu, C.C., Lin, M., Huang, H.P., Lin, Y.L., Lan, J.L., Yang, L.C., Hong, H.S. et al. (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA, 102, 4134-4139.
59. Kaniwa, N., Saito, Y., Aihara, M., Matsunaga, K., Tohkin, M., Kurose, K., Sawada, J., Furuya, H., Takahashi, Y., Muramatsu, M. et al. (2008) HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics, 9, 1617-1622.
60. Lonjou, C., Borot, N., Sekula, P., Ledger, N., Thomas, L., Halevy, S., Naldi, L., Bouwes-Bavinck, J.N., Sidoroff, A., de Toma, C. et al. (2008) A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics, 18, 99-107.
61. Romano, A., De Santis, A., Romito, A., Di Fonso, M., Venuti, A., Gasbarrini, G.B. and Manna, R. (1998) Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. Ann. Allergy Asthma Immunol., 80, 433-437.
62. Lucena, M.I., Molokhia, M., Shen, Y., Urban, T.J., Aithal, G.P., Andrade, R.J., Day, C.P., Ruiz-Cabello, F., Donaldson, P.T., Stephens, C. et al. (2011) Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology, 141, 338-347.
63. Chung, W.H., Hung, S.I., Hong, H.S., Hsih, M.S., Yang, L.C., Ho, H.C., Wu, J.Y. and Chen, Y.T. (2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 428, 486.
64. Dettling, M., Cascorbi, I., Opgen-Rhein, C. and Schaub, R. (2007) Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J., 7, 325-332.
65. Daly, A.K., Donaldson, P.T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A., Daly, M.J., Goldstein, D.B., John, S., Nelson, M.R. et al. (2009) HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet., 41, 816-819.
66. Singer, J.B., Lewitzky, S., Leroy, E., Yang, F., Zhao, X., Klickstein, L., Wright, T.M., Meyer, J. and Paulding, C.A. (2010) A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet., 42, 711-714.
67. Kim, S.H., Kim, M., Lee, K.W., Kang, H.R., Park, H.W. and Jee, Y.K. (2010) HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics, 11, 879-884.
68. Littera, R., Carcassi, C., Masala, A., Piano, P., Serra, P., Ortu, F., Corso, N., Casula, B., La Nasa, G., Contu, L. et al. (2006) HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS, 20, 1621- 1626.
69. Gatanaga, H., Yazaki, H., Tanuma, J., Honda, M., Genka, I., Teruya, K., Tachikawa, N., Kikuchi, Y. and Oka, S. (2007) HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS, 21, 264-265.
70. Chantarangsu, S., Mushiroda, T., Mahasirimongkol, S., Kiertiburanakul, S., Sungkanuparph, S., Manosuthi, W., Tantisiriwat, W., Charoenyingwattana, A., Sura, T., Chantratita, W. et al. (2009) HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet. Genomics, 19, 139-146.
71. Martin, A.M., Nolan, D., James, I., Cameron, P., Keller, J., Moore, C., Phillips, E., Christiansen, F.T. and Mallal, S. (2005) Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS, 19, 97-99.
72. Locharernkul, C., Loplumlert, J., Limotai, C., Korkij, W., Desudchit, T., Tongkobpetch, S., Kangwanshiratada, O., Hirankarn, N., Suphapeetiporn, K. and Shotelersuk, V. (2008) Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B * 1502 allele in Thai population. Epilepsia, 49, 2087-2091.
73. Kindmark, A., Jawaid, A., Harbron, C.G., Barratt, B.J., Bengtsson, O.F., Andersson, T.B., Carlsson, S., Cederbrant, K.E., Gibson, N.J., Armstrong, M. et al. (2008) Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J., 8, 186-195.